Triple Negative Breast Cancer
457
122
180
103
Key Insights
Highlights
Success Rate
61% trial completion
Published Results
65 trials with published results (14%)
Research Maturity
103 completed trials (23% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.2%
65 terminated out of 457 trials
61.3%
-25.2% vs benchmark
8%
38 trials in Phase 3/4
63%
65 of 103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 103 completed trials
Clinical Trials (457)
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
TNBC Gut Microbiota During Neoadjuvant Treatment
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Breast Cancer PSMA PET
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Cardiac Outcomes With Near-Complete Estrogen Deprivation
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors